Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06416709
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-11
Brief Title:
Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases
Sponsor:
Cell Energy Life Sciences Group Co LTD
Organization:
Cell Energy Life Sciences Group Co LTD
Study Overview
Official Title:
To Study the Clinical Treatment Plan of Lung Injury Caused by Major Infectious Diseases Treated With Stem Cells
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to conduct a prospective double-blind randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases
Detailed Description:
For patients with lung injury caused by major infectious diseases conventional antiviral and anti-inflammatory treatments may not effectively improve lung function in the short term and may increase the risk of secondary infections Therefore in the clinical management of viral pneumonia it is necessary to consider the lung tissue damage caused by acute viral replication and systemic immune stress while also focusing on the subsequent lung functional impairment due to virus clearance-induced pulmonary fibrosis Studies have shown that after peripheral intravenous administration of mesenchymal stem cells MSCs approximately 50 to 60 of the cells remain in the lung tissue within 1 hour decreasing to around 30 after 3 hours After 48 hours MSCs tend to aggregate in the liver and spleen and cell retention can still be detected 10 days later MSCs aggregation in the lung tissue can secrete cell trophic factors such as keratinocyte growth factor KGF vascular endothelial growth factor VEGF and hepatocyte growth factor HGF promoting the regeneration of type II alveolar epithelial cells improving the pulmonary microenvironment and facilitating the repair of the alveolar epithelial barrier after ARDS injuryThis study is intended to conduct a prospective double-blind randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None